164 related articles for article (PubMed ID: 27283119)
21. BM-MSCs-derived ECM modifies multiple myeloma phenotype and drug response in a source-dependent manner.
Ibraheem A; Attar-Schneider O; Dabbah M; Dolberg Jarchowsky O; Tartakover Matalon S; Lishner M; Drucker L
Transl Res; 2019 May; 207():83-95. PubMed ID: 30738861
[TBL] [Abstract][Full Text] [Related]
22. Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.
Bam R; Khan S; Ling W; Randal SS; Li X; Barlogie B; Edmondson R; Yaccoby S
BMC Cancer; 2015 Nov; 15():864. PubMed ID: 26545722
[TBL] [Abstract][Full Text] [Related]
23. Bone marrow-derived mesenchymal stem cells increase drug resistance in CD133-expressing gastric cancer cells by regulating the PI3K/AKT pathway.
Ji N; Yu JW; Ni XC; Wu JG; Wang SL; Jiang BJ
Tumour Biol; 2016 Nov; 37(11):14637-14651. PubMed ID: 27619680
[TBL] [Abstract][Full Text] [Related]
24. Cell-mediated drug delivery by gingival interdental papilla mesenchymal stromal cells (GinPa-MSCs) loaded with paclitaxel.
Brini AT; Coccè V; Ferreira LM; Giannasi C; Cossellu G; Giannì AB; Angiero F; Bonomi A; Pascucci L; Falchetti ML; Ciusani E; Bondiolotti G; Sisto F; Alessandri G; Pessina A; Farronato G
Expert Opin Drug Deliv; 2016 Jun; 13(6):789-98. PubMed ID: 26986001
[TBL] [Abstract][Full Text] [Related]
25. Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy.
Pessina A; Bonomi A; Coccè V; Invernici G; Navone S; Cavicchini L; Sisto F; Ferrari M; Viganò L; Locatelli A; Ciusani E; Cappelletti G; Cartelli D; Arnaldo C; Parati E; Marfia G; Pallini R; Falchetti ML; Alessandri G
PLoS One; 2011; 6(12):e28321. PubMed ID: 22205945
[TBL] [Abstract][Full Text] [Related]
26. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
Nefedova Y; Landowski TH; Dalton WS
Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
[TBL] [Abstract][Full Text] [Related]
27. Mesenchymal stromal cells loaded with paclitaxel induce cytotoxic damage in glioblastoma brain xenografts.
Pacioni S; D'Alessandris QG; Giannetti S; Morgante L; De Pascalis I; Coccè V; Bonomi A; Pascucci L; Alessandri G; Pessina A; Falchetti ML; Pallini R
Stem Cell Res Ther; 2015 Oct; 6():194. PubMed ID: 26445228
[TBL] [Abstract][Full Text] [Related]
28. Human mesenchymal stem cells lose their functional properties after paclitaxel treatment.
Münz F; Lopez Perez R; Trinh T; Sisombath S; Weber KJ; Wuchter P; Debus J; Saffrich R; Huber PE; Nicolay NH
Sci Rep; 2018 Jan; 8(1):312. PubMed ID: 29321693
[TBL] [Abstract][Full Text] [Related]
29. Gemcitabine-releasing mesenchymal stromal cells inhibit in vitro proliferation of human pancreatic carcinoma cells.
Bonomi A; Sordi V; Dugnani E; Ceserani V; Dossena M; Coccè V; Cavicchini L; Ciusani E; Bondiolotti G; Piovani G; Pascucci L; Sisto F; Alessandri G; Piemonti L; Parati E; Pessina A
Cytotherapy; 2015 Dec; 17(12):1687-95. PubMed ID: 26481416
[TBL] [Abstract][Full Text] [Related]
30. Mesenchymal stem cells from bone marrow regulate invasion and drug resistance of multiple myeloma cells by secreting chemokine CXCL13.
Zhang G; Miao F; Xu J; Wang R
Bosn J Basic Med Sci; 2020 May; 20(2):209-217. PubMed ID: 31538911
[TBL] [Abstract][Full Text] [Related]
31. Mesenchymal stromal cells uptake and release paclitaxel without reducing its anticancer activity.
Mariotti M; Colognato R; Rimoldi M; Rizzetto M; Sisto F; Cocce V; Bonomi A; Parati E; Alessandri G; Bagnati R; Pessina A
Anticancer Agents Med Chem; 2015; 15(3):400-5. PubMed ID: 24942547
[TBL] [Abstract][Full Text] [Related]
32. Human amniotic mesenchymal stromal cells (hAMSCs) as potential vehicles for drug delivery in cancer therapy: an in vitro study.
Bonomi A; Silini A; Vertua E; Signoroni PB; Coccè V; Cavicchini L; Sisto F; Alessandri G; Pessina A; Parolini O
Stem Cell Res Ther; 2015 Aug; 6(1):155. PubMed ID: 26315881
[TBL] [Abstract][Full Text] [Related]
33. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.
Gunn WG; Conley A; Deininger L; Olson SD; Prockop DJ; Gregory CA
Stem Cells; 2006 Apr; 24(4):986-91. PubMed ID: 16293576
[TBL] [Abstract][Full Text] [Related]
34. Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells.
Kim J; Denu RA; Dollar BA; Escalante LE; Kuether JP; Callander NS; Asimakopoulos F; Hematti P
Br J Haematol; 2012 Aug; 158(3):336-46. PubMed ID: 22583117
[TBL] [Abstract][Full Text] [Related]
35. Efficacy assessment of interferon-alpha-engineered mesenchymal stromal cells in a mouse plasmacytoma model.
Sartoris S; Mazzocco M; Tinelli M; Martini M; Mosna F; Lisi V; Indraccolo S; Moserle L; Cestari T; Riviera AP; Bifari F; Tridente G; Pizzolo G; Krampera M
Stem Cells Dev; 2011 Apr; 20(4):709-19. PubMed ID: 20695752
[TBL] [Abstract][Full Text] [Related]
36. Effect of canine mesenchymal stromal cells loaded with paclitaxel on growth of canine glioma and human glioblastoma cell lines.
Bonomi A; Ghezzi E; Pascucci L; Aralla M; Ceserani V; Pettinari L; Coccè V; Guercio A; Alessandri G; Parati E; Brini AT; Zeira O; Pessina A
Vet J; 2017 May; 223():41-47. PubMed ID: 28671070
[TBL] [Abstract][Full Text] [Related]
37. Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice.
Pessina A; Coccè V; Pascucci L; Bonomi A; Cavicchini L; Sisto F; Ferrari M; Ciusani E; Crovace A; Falchetti ML; Zicari S; Caruso A; Navone S; Marfia G; Benetti A; Ceccarelli P; Parati E; Alessandri G
Br J Haematol; 2013 Mar; 160(6):766-78. PubMed ID: 23293837
[TBL] [Abstract][Full Text] [Related]
38. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma.
Arnulf B; Lecourt S; Soulier J; Ternaux B; Lacassagne MN; Crinquette A; Dessoly J; Sciaini AK; Benbunan M; Chomienne C; Fermand JP; Marolleau JP; Larghero J
Leukemia; 2007 Jan; 21(1):158-63. PubMed ID: 17096013
[TBL] [Abstract][Full Text] [Related]
39. Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?
Xu S; De Veirman K; De Becker A; Vanderkerken K; Van Riet I
Leukemia; 2018 Jul; 32(7):1500-1514. PubMed ID: 29535427
[TBL] [Abstract][Full Text] [Related]
40. Fluorescent Immortalized Human Adipose Derived Stromal Cells (hASCs-TS/GFP+) for Studying Cell Drug Delivery Mediated by Microvesicles.
Cocce V; Balducci L; Falchetti ML; Pascucci L; Ciusani E; Brini AT; Sisto F; Piovani G; Alessandri G; Parati E; Cabeza L; Pessina A
Anticancer Agents Med Chem; 2017 Nov; 17(11):1578-1585. PubMed ID: 28356007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
